In this session, Feisal and Dr. Dale Bredesen will explore Alzheimer’s as a common and untreatable illness, how Dr. Bredesen’s research suggests a new model that has led to the first successful clinical trial. When combining the results and early detection and symptom recognition, it is now possible to make Alzheimer’s optional.
Dr. Dale Bredesen: Dr. Bredesen graduated from Caltech and received his MD from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow with Nobel laureate Prof. Stanley Prusiner. He was the Founding President of the Buck Institute for Research on Aging.The Bredesen Laboratory studied basic mechanisms underlying the neurodegenerative process, and the translation into effective therapeutics for Alzheimer’s disease, leading to the publication of over 220 research papers.
He established the Alzheimer’s Drug Development Network with Dr. Varghese John, leading to the identification of new classes of therapeutics for Alzheimer’s disease.His work led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and Alzheimer’s disease, with a precision medicine protocol, and a recent successful proof-of-concept trial. Dr. Bredesen is the author of two New York Times best sellers. He is currently a professor at UCLA.
